Translational Neuroscience Optimization of GlyT1 Inhibitor

Phase 2

Completed

• Conditions: Cognitive Impairments Associated With Schizophrenia
• Interventions: Drug: Placebo; Drug: PF-03463275

• Registration Number: NCT01911676
• Lead Sponsor: Yale University

Brief Summary

This is a Phase II, randomized, double-blind, placebo-controlled, cross-over POC study of stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this study is to test the efficacy of treatment with one of two does of a glycine transporter inhibitor (GlyT1I) combined with cognitive remediation to enhavce cognitive function. Subjects will be randomized to one of two doses of the glycine transporter inhibitor (GlyT1I) and placebo twice daily in addition to their antipsychotic medication for 2 treatment periods, each lasting a minimum of 5 weeks. Treatment periods will be separated by a washout period lasting approximately 3 weeks.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-07-10
• Study First Submitted QC: 2013-07-26
• Study First Posted: 2013-07-30
• Study Start: 2013-08
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Results First Submitted: 2021-07-08
• Results First Submitted QC: 2023-02-23
• Results First Posted: 2023-02-27
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-15
• Last Update Posted: 2024-08-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 71

Inclusion Criteria

• 1. Males or females 21 to 65 years of age (inclusive).
• 2. Diagnosis of Schizophrenia or Schizoaffective Disorder
• 3. Able to provide written informed consent.
• 4. Only CYP2D6 extensive metabolizers.

Read More

Exclusion Criteria

• 1. No ongoing acute medical issues
• 2. Clinically significant ECG abnormality
• 3. Blood donation within eight weeks of the start of the study
• 4. Current treatment with Clozapine

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo- no active dose of PF-03463275.
PF-03463275 Active Dose #1	PF-03463275	Active dose between 40mg
PF-03463275 Active Dose #2	PF-03463275	Active dose between 60mg

Primary Outcome Measures

Name	Time	Method
Change in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)	Change from baseline in cognitive measures at approximately 5 weeks. Mean scores were calculated per time point for each arm.	To test the efficacy of PF-03463275 on cognitive test performance specifically, the MCCB composite score was used. The MCCB consists of 10 tests and provides standard scores and percentiles for each of seven cognitive domains and an overall composite score. Domains assessed include: speed of processing, attention/vigilance, working memory (verbal and visual), verbal learning, visual learning, reasoning and problem solving, and social cognition. The MCCB overall composite score is presented as a T-score. The range of T-scores is between 0 to 100 with a mean of 50 and standard deviation of 10. Higher scores indicate better overall cognitive functioning.

Secondary Outcome Measures

Name	Time	Method
Alteration in Symptom Domain Scores and Event Related Potentials (ERPs) With PF-03463275	Change from Baseline at approximately 1 week	To determine whether PF-03463275 impacts symptom domain scores and visual event related potentials (ERPs), analogous to long-term potentiation (LTP) with PF-03463275 treatment. A more positive value reflects a better outcome - there is no established range to report. A Z-score of 0 indicates the mean score. A positive z-score indicates the mean is higher than average.

Trial Locations

Locations (2)

Connecticut Mental Health Center; 🇺🇸 New Haven, Connecticut, United States

VA Connecticut Healthcare System; 🇺🇸 West Haven, Connecticut, United States